Compare Citius Pharmaceuticals Inc (CTXR) vs Western Alliance Bancorporation (WAL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Western Alliance Bancorporation — how do they compare? Citius Pharmaceuticals Inc trades at $0.69 (market cap $20.01M), while Western Alliance Bancorporation trades at $82.06 (market cap $8.89B). The key difference: Western Alliance Bancorporation is far larger — about 444.3× Citius Pharmaceuticals Inc's market cap, and Western Alliance Bancorporation pays a 2.06% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| CTXR | WAL | |
|---|---|---|
Market Cap | $20.01M | $8.89B |
Sector | Health | Financials |
52-Week High | $1.82 | $96.08 |
52-Week Low | $0.48 | $66.70 |
Enterprise Value | $16.23M | — |
Dividend Yield | — | 2.06% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR is trading at $0.7126, up 5.26% today, with strong technical momentum showing bullish moving average signals. The company shows significant revenue growth potential with LYMPHIR commercialization expanding, though currently operates at substantial losses with a -823% net income margin. Analyst sentiment remains overwhelmingly positive with 83% buy ratings, reflecting optimism about the oncology pipeline and recent commercial progress.
The investment case hinges on successful LYMPHIR commercialization offsetting current losses, with strong institutional support providing runway. Key risks include execution challenges in scaling operations and the capital-intensive nature of biopharmaceutical development. The stock presents high-risk, high-reward potential for investors comfortable with clinical-stage biotech volatility.
Western Alliance Bancorporation (WAL) trades at $81.64, up 1.44% today, with a neutral technical signal and bullish analyst consensus. The stock shows strong fundamentals, including a P/E of 9.2 and net income margin of 25.43%, supported by recent earnings beats. Recent developments include the launch of WA VenueX, an institutional financial platform, and recognition as Arizona's top bank by Forbes in 2026.
The outlook for WAL is positive, with a consensus price target of $93.86 implying 15% upside, driven by revenue growth and profitability. Risks include negative operating cash flow and high interest expenses. Institutional sentiment is mixed, with some firms reducing stakes, but overall analyst ratings remain heavily bullish.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Western Alliance Bancorporation
Western Alliance Bancorporation is a top-performing bank holding company that operates a dual business model: high-touch regional banking and specialized national business lines. It serves niche industries—including technology, life sciences, and homeowners associations—providing sophisticated commercial lending and treasury solutions that bridge the gap between regional service and national scale.
Read more on WAL →
